A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Abstract | INTRODUCTION: METHODS:
Carboplatin (AUC = 6 mg/mL/min) and paclitaxel (200 mg/m²) were administered on day 1 of each 21-day cycle up to a maximum of six cycles. Oral linifanib (7.5 mg) was given to six patients once daily throughout all cycles and escalated to 12.5 mg/day in a second cohort of six patients. RESULTS: CONCLUSIONS:
|
Authors | Hidehito Horinouchi, Noboru Yamamoto, Hiroshi Nokihara, Takeshi Horai, Makoto Nishio, Fumiyoshi Ohyanagi, Atsushi Horiike, Kazuhiko Nakagawa, Masaaki Terashima, Takafumi Okabe, Hiroyasu Kaneda, Mark D McKee, Dawn M Carlson, Hao Xiong, Tomohide Tamura |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 74
Issue 1
Pg. 37-43
(Jul 2014)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 24807459
(Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Indazoles
- Phenylurea Compounds
- Protein Kinase Inhibitors
- Carboplatin
- linifanib
- Receptors, Platelet-Derived Growth Factor
- Receptors, Vascular Endothelial Growth Factor
- Paclitaxel
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Carboplatin
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Carcinoma
(blood, drug therapy, pathology, secondary)
- Carcinoma, Non-Small-Cell Lung
(blood, drug therapy, pathology)
- Chemotherapy-Induced Febrile Neutropenia
(physiopathology)
- Cohort Studies
- Dose-Response Relationship, Drug
- Female
- Humans
- Indazoles
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Japan
- Leukopenia
(chemically induced, physiopathology)
- Lung
(drug effects, pathology)
- Lung Neoplasms
(blood, drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Paclitaxel
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Phenylurea Compounds
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Protein Kinase Inhibitors
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Receptors, Platelet-Derived Growth Factor
(antagonists & inhibitors)
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors)
- Severity of Illness Index
- Thrombocytopenia
(chemically induced, physiopathology)
- Tumor Burden
(drug effects)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|